The use of [64Cu]Cu-DOTAGA-WL-12 as a tool to evaluate the dynamic expression of tumor PD-L1 and target engagement of therapeutic anti-PD-L1 mAbs was successfully demonstrated (190). This evidence concerns the gene CD274 and neoplasm.